MedTrace Logo

Trial of Ginkgo as a Treatment for Cognitive Problems in Multiple Sclerosis

NCT00841321 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2014-06-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see if treatment with Ginkgo improves cognitive function in people with multiple sclerosis who have cognitive problems.

Conditions

Interventions

DRUG

Ginkgo biloba

120 mg orally twice a day for 12 weeks

DRUG

Placebo

One capsule orally twice a day for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Dennis N. Bourdette, MD · Portland VA Medical Center, Portland, OR

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2010-11-30
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00841321 on ClinicalTrials.gov